Innova Biosciences expands UK facility and increases laboratory space
The move comes in response to increasing demand for its products and services.
Innova Biosciences has expanded its UK footprint to enable the company to increase its laboratory space.
Innova’s sales and marketing teams have moved from the Babraham Research Park to Ashwell Point in Sawston, accommodating another 2500 sq ft of office space to double the company’s footprint across the two sites. The move enables both extra laboratory and office space to allow for further growth as the company continues to expand.
Innova Biosciences are experts in easy-to-use, cutting-edge bioconjugation technologies and services, with the flexibility to support scientists from academia through to commercial manufacturing. Products are based on its antibody and protein labeling, nanoparticle, oligonucleotide labeling, and phosphate detection enzyme assay technologies. The move marks the next stage in the company’s development, and comes in response to increasing demand for its products and services.
Dr Nick Gee, CEO of Innova Biosciences, commented: “Innova has expanded its laboratory space to accommodate the need for increased and continuous development of new products based on our bioconjugation technology, in addition to the custom services offering which has also grown year on year.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance